Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab.

Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, Savoldo B, Ferrone S, Dotti G, Sconocchia G.

Int J Cancer. 2019 Sep 3. doi: 10.1002/ijc.32663. [Epub ahead of print]

PMID:
31479522
2.

An evaluation of enasidenib for the treatment of acute myeloid leukemia.

Del Principe MI, Paterno G, Palmieri R, Maurillo L, Buccisano F, Venditti A.

Expert Opin Pharmacother. 2019 Aug 27:1-8. doi: 10.1080/14656566.2019.1654456. [Epub ahead of print]

PMID:
31454277
3.

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.

Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S.

Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.

PMID:
31395600
4.

A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group.

Marchesi F, Cattaneo C, Criscuolo M, Delia M, Dargenio M, Del Principe MI, Spadea A, Fracchiolla NS, Melillo L, Perruccio K, Alati C, Russo D, Garzia M, Brociner M, Cefalo M, Armiento D, Cesaro S, Decembrino N, Mengarelli A, Tumbarello M, Busca A, Pagano L; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group.

Am J Hematol. 2019 Oct;94(10):1104-1112. doi: 10.1002/ajh.25585. Epub 2019 Aug 9.

PMID:
31321791
5.

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.

Iaccarino L, Ottone T, Alfonso V, Cicconi L, Divona M, Lavorgna S, Travaglini S, Ferrantini A, Falconi G, Baer C, Usai M, Forghieri F, Venditti A, Del Principe MI, Arcese W, Voso MT, Haferlach T, Lo-Coco F.

Am J Hematol. 2019 Oct;94(10):1091-1097. doi: 10.1002/ajh.25573. Epub 2019 Jul 23.

PMID:
31292998
6.

The emerging role of measurable residual disease detection in AML in morphologic remission.

Buccisano F, Maurillo L, Schuurhuis GJ, Del Principe MI, Di Veroli A, Gurnari C, Venditti A.

Semin Hematol. 2019 Apr;56(2):125-130. doi: 10.1053/j.seminhematol.2018.09.001. Epub 2018 Sep 19. Review.

PMID:
30926088
7.

Fungaemia in haematological malignancies: SEIFEM-2015 survey.

Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, Verga L, Fracchiolla N, Vianelli N, Del Principe MI, Picardi M, Tumbarello M, Aversa F, Busca A, Pagano L; SEIFEM Group (Sorveglianza Epidemiologica Infezioni nelle Emopatie).

Eur J Clin Invest. 2019 May;49(5):e13083. doi: 10.1111/eci.13083. Epub 2019 Mar 7.

PMID:
30735240
8.

'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.

Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, Delia M, Potenza L, Farina F, Ballanti S, Decembrino N, Castagnola C, Nadali G, Fanci R, Orciulo E, Veggia B, Offidani M, Melillo L, Manetta S, Tumbarello M, Venditti A, Busca A, Aversa F, Pagano L; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group .

J Antimicrob Chemother. 2019 Apr 1;74(4):1062-1068. doi: 10.1093/jac/dky550.

PMID:
30649413
9.

Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases.

Candoni A, Klimko N, Busca A, Di Blasi R, Shadrivova O, Cesaro S, Zannier ME, Verga L, Forghieri F, Calore E, Nadali G, Simonetti E, Muggeo P, Quinto AM, Castagnola C, Cellini M, Del Principe MI, Fracchiolla N, Melillo L, Piedimonte M, Zama D, Farina F, Giusti D, Mosna F, Capelli D, Delia M, Picardi M, Decembrino N, Perruccio K, Vallero S, Aversa F, Fanin R, Pagano L; SEIFEM Group (Epidemiological Surveillance of Infections in Haematological Diseases).

Mycoses. 2019 Mar;62(3):252-260. doi: 10.1111/myc.12884. Epub 2019 Jan 22.

PMID:
30565742
10.

Rhodotorula infection in haematological patient: Risk factors and outcome.

Potenza L, Chitasombat MN, Klimko N, Bettelli F, Dragonetti G, Del Principe MI, Nucci M, Busca A, Fracchiolla N, Sciumè M, Spolzino A, Delia M, Mancini V, Nadali GP, Dargenio M, Shadrivova O, Bacchelli F, Aversa F, Sanguinetti M, Luppi M, Kontoyiannis DP, Pagano L.

Mycoses. 2019 Mar;62(3):223-229. doi: 10.1111/myc.12875. Epub 2018 Dec 28.

PMID:
30525252
11.

Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.

Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Semin Hematol. 2018 Oct;55(4):209-214. doi: 10.1053/j.seminhematol.2018.02.006. Epub 2018 Feb 21. Review.

PMID:
30502849
12.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
13.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
14.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
15.

Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.

Buccisano F, Maurillo L, Del Principe MI, Di Veroli A, De Bellis E, Biagi A, Zizzari A, Rossi V, Rapisarda V, Amadori S, Voso MT, Lo-Coco F, Arcese W, Venditti A.

Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7. Review.

PMID:
29495904
16.

Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia.

Ottone T, Alfonso V, Iaccarino L, Hasan SK, Mancini M, Divona M, Lavorgna S, Cicconi L, Panetta P, Maurillo L, Del Principe MI, Irno Consalvo M, Franceschini L, Angelini DF, Battistini L, Guerrera G, De Bardi M, Fabiani E, Falconi G, Arcese W, Amadori S, Buccisano F, Venditti A, Voso MT, Lo-Coco F.

Am J Hematol. 2018 May;93(5):E120-E123. doi: 10.1002/ajh.25061. Epub 2018 Feb 24. No abstract available.

17.

SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.

Busca A, Cesaro S, Teofili L, Delia M, Cattaneo C, Criscuolo M, Marchesi F, Fracchiolla NS, Valentini CG, Farina F, Di Blasi R, Prezioso L, Spolzino A, Candoni A, Del Principe MI, Verga L, Nosari A, Aversa F, Pagano L; SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia).

Expert Rev Hematol. 2018 Feb;11(2):155-168. doi: 10.1080/17474086.2018.1420472. Epub 2018 Jan 3.

PMID:
29285951
18.

Thrombosis in adult patients with acute leukemia.

Del Principe MI, Del Principe D, Venditti A.

Curr Opin Oncol. 2017 Nov;29(6):448-454. doi: 10.1097/CCO.0000000000000402. Review.

PMID:
28841588
19.

Treatment of Low-Blast Count AML using Hypomethylating Agents.

De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Review.

20.

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.

Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G.

Front Immunol. 2017 Apr 27;8:457. doi: 10.3389/fimmu.2017.00457. eCollection 2017. Review.

21.

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A.

Bone Marrow Transplant. 2017 Mar;52(3):473-475. doi: 10.1038/bmt.2016.308. Epub 2016 Dec 12. No abstract available.

PMID:
27941782
22.

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. eCollection 2016. Review.

23.

Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.

Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Perriello V, Busca A, Aversa F, Fanci R, Melillo L, Lessi F, Del Principe MI, Cattaneo C, Tumbarello M; HaematologicMalignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne(SEIFEM) group, Italy.

Am J Hematol. 2016 Nov;91(11):1076-1081. doi: 10.1002/ajh.24489. Epub 2016 Jul 29.

24.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
25.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
26.

A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature.

Del Principe MI, Sarmati L, Cefalo M, Fontana C, De Santis G, Buccisano F, Maurillo L, De Bellis E, Postorino M, Sconocchia G, Del Poeta G, Sanguinetti M, Amadori S, Pagano L, Venditti A.

Mycoses. 2016 Sep;59(9):594-601. doi: 10.1111/myc.12508. Epub 2016 Apr 8. Review.

PMID:
27061932
27.

Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?

Girmenia C, Annino L, Mariotti B, Fanci R, Minotti C, Spadea A, Carotti A, Piedimonte M, Chierichini A, Cerchiara E, Caselli D, Cupelli L, Arcioni F, Bertaina A, Ribersani M, Proia A, Mengarelli A, Perriello V, Torelli GF, Di Gioia M, Del Principe MI, Cassetta MI, Fallani S, Novelli A.

Med Mycol. 2016 Jul 1;54(5):445-58. doi: 10.1093/mmy/myw001. Epub 2016 Feb 11.

PMID:
26868905
28.

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage.

Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G.

Oncotarget. 2016 Jan 12;7(2):2070-9. doi: 10.18632/oncotarget.6529.

29.

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G.

Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.

30.

A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy.

Postorino M, Pupo L, Provenzano I, Del Principe MI, Buccisano F, Franceschini L, Rizzo M, Nasso D, Meconi F, Onnis I, Vaccarini S, Zizzari A, Anemona L, Mauramati S, Bruno E, Cantonetti M, Amadori S.

Ann Hematol. 2016 Jan;95(1):153-154. doi: 10.1007/s00277-015-2503-z. Epub 2015 Oct 7. No abstract available.

PMID:
26442854
31.

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma.

Coppola A, Arriga R, Lauro D, Del Principe MI, Buccisano F, Maurillo L, Palomba P, Venditti A, Sconocchia G.

Front Med (Lausanne). 2015 May 26;2:33. doi: 10.3389/fmed.2015.00033. eCollection 2015. Review.

32.

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study.

Napolitano M, Valore L, Malato A, Saccullo G, Vetro C, Mitra ME, Fabbiano F, Mannina D, Casuccio A, Lucchesi A, Del Principe MI, Candoni A, Di Raimondo F, Siragusa S.

Leuk Lymphoma. 2016;57(1):116-9. doi: 10.3109/10428194.2015.1046864. Epub 2015 May 25.

PMID:
25944377
33.

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Ann Hematol. 2015 Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5. Epub 2015 Apr 14.

PMID:
25869029
34.

Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.

Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014075. doi: 10.4084/MJHID.2014.075. eCollection 2014. Review.

35.

Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24.

36.

Advances in the treatment of elderly and frail patients with acute myeloid leukemia.

Amadori S, Del Principe MI, Venditti A.

Curr Opin Oncol. 2014 Nov;26(6):663-9. doi: 10.1097/CCO.0000000000000124. Review.

PMID:
25162330
37.

Extensive toxic epidermal necrolysis following brentuximab vedotin administration.

Del Principe MI, Sconocchia G, Buccisano F, Cefalo M, Di Veroli A, De Santis G, Nasso D, Maurillo L, Anemona L, Postorino M, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2015 Feb;94(2):355-6. doi: 10.1007/s00277-014-2148-3. Epub 2014 Jul 2. No abstract available.

PMID:
24981690
38.

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM, Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G.

Ann Hematol. 2014 Oct;93(10):1765-74. doi: 10.1007/s00277-014-2117-x. Epub 2014 Jun 13.

PMID:
24923451
39.

High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma.

Del Principe MI, Buccisano F, Cefalo M, Maurillo L, Di Caprio L, Di Piazza F, Sarlo C, De Angelis G, Irno Consalvo M, Fraboni D, De Santis G, Ditto C, Postorino M, Sconocchia G, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2014 Sep;93(9):1509-13. doi: 10.1007/s00277-014-2080-6. Epub 2014 Apr 22.

PMID:
24752416
40.

Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.

Del Principe MI, Cefalo M, Buccisano F, Anemona L, Sarlo C, Di Caprio L, De Santis G, Giacobbi E, Maurillo L, Postorino M, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2014 Sep;93(9):1611-2. doi: 10.1007/s00277-014-2010-7. Epub 2014 Jan 23. No abstract available.

PMID:
24452366
41.

Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.

Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di Veroli A, Nasso D, Ceresoli E, Postorino M, Di Piazza F, Colandrea G, Conti F, Del Poeta G, Amadori S, Venditti A.

Thromb Res. 2013 Nov;132(5):511-4. doi: 10.1016/j.thromres.2013.08.007. Epub 2013 Aug 16.

PMID:
24090605
42.

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2013 Jun 3;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013.

43.

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A.

Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28.

44.

Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes.

Buccisano F, Maurillo L, Neri B, Masala S, Mauriello A, Del Principe MI, Ditto C, Sarlo C, Cefalo M, Di Caprio L, Loreni G, Cicconi L, Amadori S, Venditti A.

J Clin Oncol. 2013 Apr 10;31(11):e189-91. doi: 10.1200/JCO.2012.45.3209. Epub 2013 Feb 19. No abstract available.

PMID:
23423741
45.

Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?

Venditti A, Del Principe MI, Maurillo L, Buccisano F, Amadori S.

Transl Pediatr. 2013 Jan;2(1):43-5. doi: 10.3978/j.issn.2224-4336.2012.10.01. No abstract available.

46.

Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia.

Del Poeta G, Dal Bo M, Del Principe MI, Pozzo F, Rossi FM, Zucchetto A, Bomben R, Degan M, Rasi S, Rossi D, Bulian P, Gaidano G, Amadori S, Gattei V.

Br J Haematol. 2013 Feb;160(3):415-8. doi: 10.1111/bjh.12128. Epub 2012 Nov 20. No abstract available.

PMID:
23167503
47.

A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.

D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P.

Am J Hematol. 2012 Jun;87(6):628-31. doi: 10.1002/ajh.23170. Epub 2012 Mar 28.

48.

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.

Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe MI, Gorgone A, Pozzato G, Gaidano G, Del Poeta G, Malavasi F, Deaglio S, Gattei V.

Leukemia. 2012 Jun;26(6):1301-12. doi: 10.1038/leu.2011.369. Epub 2012 Jan 6.

PMID:
22289918
49.

Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis.

D'Arena G, Rossi G, Minervini MM, Savino L, D'Auria F, Laurenti L, Del Principe MI, Deaglio S, Biagi A, De Martino L, De Feo V, Statuto T, Musto P, Del Poeta G.

Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):915-23.

PMID:
22230398
50.

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Blood. 2012 Jan 12;119(2):332-41. doi: 10.1182/blood-2011-08-363291. Epub 2011 Oct 28. Review.

Supplemental Content

Loading ...
Support Center